Esperion Therapeutics is a late-stage lipid management company focused on developing and commercializing once-daily oral therapies for the treatment of patients with elevated hypercholesterolemia. Esperion's lead product candidate, Bempedoic Acid, is a first-in-class, non-statin therapy that works in the liver to block cholesterol biosynthesis and reduce low density lipoprotein cholesterol (LDL-C). Bempedoic Acid is converted into a coenzyme derivative in the liver which directly inhibits ATP citrate lyase (ACL). Inhibition of ACL results in reduced cholesterol synthesis and upregulation of LDL receptor activity in the blood, thus promoting the removal of LDL-C from the blood. Elevated LDL-C is a significant risk factor for cardiovascular disease. About 200 million people worldwide live with elevated LDL-C levels, representing a multi-billion dollar market opportunity.